3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Colorectal Neoplasms
93
Stomach Neoplasms
56
Rectal Neoplasms
51
Colonic Neoplasms
47
Pancreatic Neoplasms
21
Neoplasms
14
Carcinoma, Hepatocellular
14
Neoplasm Metastasis
13
Adenocarcinoma
10
Parkinson Disease 4, Autosomal Dominant Lewy Body
9
Lymphoma, Large B-Cell, Diffuse
9
Cholangiocarcinoma
8
Adenocarcinoma Of Esophagus
8
Esophageal Neoplasms
5
Biliary Tract Neoplasms
5
Neurotoxicity Syndromes
4
Esophageal Squamous Cell Carcinoma
4
Lymphoma, Extranodal NK-T-Cell
3
Gastrointestinal Neoplasms
3
Gallbladder Neoplasms
3
Peritoneal Neoplasms
2
Lymphoma
2
Liver Neoplasms
2
Hepatoblastoma
2
Gastrointestinal Diseases
2
Colorectal Adenocarcinoma
2
Testicular Neoplasms
1
Testicular Germ Cell Tumor
1
Teratoma
1
Spinocerebellar Degenerations
1
Interventions
pasireotide
2
Octreotide
2
Everolimus
2
lutetium Lu 177 dotatate
1
lanreotide
1
amino-acid, glucose, and electrolyte solution
1
Temozolomide
1
Sunitinib
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
Oxaliplatin
1
Leucovorin
1
Folfox protocol
1
Fluorouracil
1
Capecitabine
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Gastro-enteropancreatic neuroendocrine tumor
×
Oxaliplatin
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled